Verily steps on a few toes at JPM debut
Verily was one of the most-talked-about debutants at this year’s J.P. Morgan ball. For the first time in its five-year history, the Alphabet life sciences spinout presented to some of the 9,000 health care executives and investors who descended upon Union Square, and Verily’s mercurial CEO, Andy Conrad, faced pressure both to impress and entertain.
It seemed to go well.
But not everyone was thrilled with the particulars of Conrad’s presentation — especially Dexcom’s chief executive, who was caught off-guard by some of the specifics Conrad revealed. Those included a potential movement-tracking feature on the device as well as images that CEO Kevin Sayer said hadn’t previously been made public.
“He said things about it publicly that he wasn’t supposed to,” Sayer told STAT.
Read more.
It seemed to go well.
But not everyone was thrilled with the particulars of Conrad’s presentation — especially Dexcom’s chief executive, who was caught off-guard by some of the specifics Conrad revealed. Those included a potential movement-tracking feature on the device as well as images that CEO Kevin Sayer said hadn’t previously been made public.
“He said things about it publicly that he wasn’t supposed to,” Sayer told STAT.
Read more.
.png)
No hay comentarios:
Publicar un comentario